Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Completed 4Not yet recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

pembrolizumab 225Cyclophosphamide 194Radiotherapy 181Nivolumab 181Carboplatin 155Paclitaxel 114Cisplatin 113Dexamethasone 111Radiosurgery 103Magnetic Resonance Spectroscopy 98Surveys and Questionnaires 92Ipilimumab 82Doxorubicin 80Lenalidomide 77durvalumab 76Rituximab 75atezolizumab 73Radiation 72venetoclax 69Standard of Care 69fludarabine 68Gemcitabine 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Docetaxel 60Oxaliplatin 59Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Vancomycin × Clear all
NCT04729322 2025-12-23

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
15 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡